» Articles » PMID: 21600517

Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients: Clinical Guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Abstract

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.

Citing Articles

Familial Hypercholesterolemia: A Comprehensive Review of Advances in Treatment Strategies and the Role of Patient Beliefs.

Bakour H, Hussain Timraz J, Bin Saddiq B, Alghamdi N, Irfan Thalib H, Alyarimi M Cureus. 2025; 17(1):e78032.

PMID: 40013201 PMC: 11862280. DOI: 10.7759/cureus.78032.


A strategy to increase identification of patients with Familial Hypercholesterolemia: Application of the Simon Broome lipid criteria in a large-scale retrospective analysis.

Fleming J, Sullivan R, Alfego D, Leach N, Richman T, Rafalko J Am J Prev Cardiol. 2025; 21:100930.

PMID: 39896055 PMC: 11787606. DOI: 10.1016/j.ajpc.2025.100930.


Healthcare dashboard technologies and data visualization for lipid management: A scoping review.

Samadbeik M, Engstrom T, Lobo E, Kostner K, Austin J, Pole J BMC Med Inform Decis Mak. 2024; 24(1):352.

PMID: 39574106 PMC: 11583543. DOI: 10.1186/s12911-024-02730-w.


Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia.

Liu J, Bellows B, Jacobs Jr D, Woo J, Urbina E, Balte P Circulation. 2024; 150(21):1741-1744.

PMID: 39556651 PMC: 11581617. DOI: 10.1161/CIRCULATIONAHA.124.069792.


Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial.

Johnson C, Chen J, McGowan M, Tricou E, Card M, Pettit A Implement Sci. 2024; 19(1):30.

PMID: 38594685 PMC: 11003060. DOI: 10.1186/s13012-024-01355-x.